Search results for "harm"

showing 10 items of 13866 documents

Population pharmacokinetic meta-analysis of individual data to design the first randomized efficacy trial of vancomycin in neonates and young infants.

2019

Abstract Objectives In the absence of consensus, the present meta-analysis was performed to determine an optimal dosing regimen of vancomycin for neonates. Methods A ‘meta-model’ with 4894 concentrations from 1631 neonates was built using NONMEM, and Monte Carlo simulations were performed to design an optimal intermittent infusion, aiming to reach a target AUC0–24 of 400 mg·h/L at steady-state in at least 80% of neonates. Results A two-compartment model best fitted the data. Current weight, postmenstrual age (PMA) and serum creatinine were the significant covariates for CL. After model validation, simulations showed that a loading dose (25 mg/kg) and a maintenance dose (15 mg/kg q12h if &lt…

0301 basic medicinePediatricsvancomycininfusion procedures0302 clinical medicinenewbornMedicinePharmacology (medical)Randomized Controlled Trials as Topiceducation.field_of_studyMaintenance doseAnti-Bacterial Agents3. Good healthInfectious Diseasesdrug maintenance doseResearch DesignArea Under CurveData Interpretation Statisticalcreatinine testsVancomycinMonte Carlo Methodmedicine.drugMicrobiology (medical)medicine.medical_specialty030106 microbiologyPopulationGestational AgeMicrobial Sensitivity TestsLoading doseRS03 medical and health sciencesPharmacokineticsdrug loading dose030225 pediatricsHumanssteady stateeducationPharmacologyDose-Response Relationship Drugbusiness.industryBody WeightInfant NewbornPostmenstrual AgeinfantNONMEMRegimen[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieregimen[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologiebusinessserum
researchProduct

(+)-Pentazocine reduces oxidative stress and apoptosis in microglia following hypoxia/reoxygenation injury

2016

Abstract Background Sigma-1 receptors (σ 1 R) are highly expressed in neurons as well as microglia and have been shown to modulate the inflammatory response in the central nervous system and thus may serve as possible target for neuroprotective strategies. The aim of the present study was to test the effect of (+)-pentazocine, a putative σ 1 R agonist, in an in vitro model of microglia activation. Methods Microglia (BV2 cells) was exposed (3 h) to 1% oxygen and reoxygenation was allowed for 24 h. Cells were treated with different concentrations (1, 10, 25 and 50 μM) of (+)-pentazocine in the presence or absence of NE-100 (1 μM), a well established σ 1 R antagonist. Cell viability and apopto…

0301 basic medicinePentazocineSigma receptorCell SurvivalmicrogliaApoptosisPharmacologyBiologymedicine.disease_causeNeuroprotection(+)-PentazocineCell LineMice03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePentazocine; microglia; SIGMAmedicineAnimalsReceptors sigmaViability assayAnnexin A5PhosphorylationHypoxiaMembrane Potential MitochondrialMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3MicrogliaAnimalGeneral NeuroscienceApoptosiOxidative StreGlutathioneGlutathioneOxidative Stress030104 developmental biologymedicine.anatomical_structurePentazocineBiochemistrychemistryApoptosis030217 neurology & neurosurgeryIntracellularOxidative stressSIGMAmedicine.drug
researchProduct

PPAR Agonists, Atherogenic Dyslipidemia and Cardiovascular Risk.

2016

Peroxisome proliferator-activated receptors (PPAR) are implicated in the pathology of several metabolic diseases including obesity, diabetes, and atherosclerosis. PPAR agonists exert multiple lipid modifying actions which are beneficial to the prevention of atherosclerosis. Such benefits in lipid lowering actions include improvements in atherogenic dyslipidemia that seems to be particularly expressed in individuals at higher cardiovascular (CV) risk. In addition, the favorable effects of PPAR agonists on different cardio-metabolic parameters are established in several metabolic conditions, such as diabetes mellitus, insulin resistance, and heightened systemic inflammation. The goal of this …

0301 basic medicinePeroxisome Proliferator-Activated Receptormedicine.medical_specialtyPeroxisome Proliferator-Activated ReceptorsPeroxisome proliferator-activated receptor030204 cardiovascular system & hematologyBioinformaticsSystemic inflammationPPAR agonist03 medical and health sciences0302 clinical medicineInsulin resistanceRisk FactorsCardiovascular DiseaseInternal medicineDiabetes mellitusDrug DiscoverymedicineAnimalsHumansDyslipidemiasHypolipidemic AgentsPharmacologychemistry.chemical_classificationClinical Trials as TopicHypolipidemic Agentmedicine.diagnostic_testAnimalbusiness.industryRisk FactorAtherogenic dyslipidemiaCardiovascular riskmedicine.diseaseAtherosclerosisObesityThiazoles030104 developmental biologyEndocrinologyDyslipidemiachemistryCardiovascular DiseasesAtherosclerosilipids (amino acids peptides and proteins)medicine.symptomLipid profilebusinessHumanLipoproteinCurrent pharmaceutical design
researchProduct

Impact of elastin-derived VGVAPG peptide on bidirectional interaction between peroxisome proliferator-activated receptor gamma (Pparγ) and beta-galac…

2018

The process of degradation of the elastin-rich extracellular matrix produces elastin-derived peptides (EDPs). Different types of EDPs are detectable in the cerebrospinal fluid in healthy individuals and in patients after ischemic stroke. To date, it has been demonstrated that EDPs can regulate the development of insulin resistance in mice in a peroxisome proliferator-activated receptor gamma (Pparγ)-dependent manner. Therefore, the aim of this study was to investigate the impact of the elastin-derived valine-glycine-valine-alanine-proline-glycine (VGVAPG) peptide on Pparγ and beta-galactosidase (β-Gal) expression in mouse cortical astrocytes in vitro. Primary astrocytes were maintained in D…

0301 basic medicinePeroxisome proliferator-activated receptorPeptideEDPPparγ03 medical and health sciencesMice0302 clinical medicinemedicineAnimalsRNA MessengerRNA Small InterferingReceptorCells CulturedPharmacologychemistry.chemical_classificationMessenger RNAGene knockdownGeneral Medicinebeta-GalactosidaseIn vitroCell biologyElastinElastin-derived peptidesPPAR gamma030104 developmental biologymedicine.anatomical_structurechemistryVGVAPGAstrocytesβ-GalFemaleAstrocyteOligopeptides030217 neurology & neurosurgeryFetal bovine serumAstrocyteNaunyn-Schmiedebergs Archives of Pharmacology
researchProduct

Pharmacogenomics of Scopoletin in Tumor Cells

2016

Drug resistance and the severe side effects of chemotherapy necessitate the development of novel anticancer drugs. Natural products are a valuable source for drug development. Scopoletin is a coumarin compound, which can be found in several Artemisia species and other plant genera. Microarray-based RNA expression profiling of the NCI cell line panel showed that cellular response of scopoletin did not correlate to the expression of ATP-binding cassette (ABC) transporters as classical drug resistance mechanisms (ABCB1, ABCB5, ABCC1, ABCG2). This was also true for the expression of the oncogene EGFR and the mutational status of the tumor suppressor gene, TP53. However, mutations in the RAS onc…

0301 basic medicinePharmaceutical ScienceATP-binding cassette transporterDrug resistancePharmacologycoumarinAnalytical Chemistrychemistry.chemical_compound0302 clinical medicineNeoplasmsDrug DiscoveryABC-transportermicroarraysNF-kappa BABCB5Drug Resistance MultipleGene Expression Regulation NeoplasticMolecular Docking SimulationDrug developmentChemistry (miscellaneous)030220 oncology & carcinogenesisherbal medicineMolecular MedicineSignal TransductionTumor suppressor geneProtein Array AnalysisBiologyArticlelcsh:QD241-44103 medical and health scienceslcsh:Organic chemistrymultidrug resistanceCell Line TumorScopoletinHumansPhysical and Theoretical ChemistryTranscription factorScopoletinOncogenePlant ExtractsOrganic ChemistryTranscription Factor RelAphytotherapy030104 developmental biologyArtemisiachemistryDrug Resistance NeoplasmPharmacogeneticsCancer researchABC-transporter; cluster analysis; coumarin; herbal medicine; microarrays; multidrug resistance; phytotherapyATP-Binding Cassette Transporterscluster analysisMolecules
researchProduct

Cytotoxicity and mode of action of a naturally occurring naphthoquinone, 2-acetyl-7-methoxynaphtho[2,3-b]furan-4,9-quinone towards multi-factorial dr…

2017

Abstract Introduction Malignacies are still a major public concern worldwide and despite the intensive search of new chemotherapeutic agents, treatment still remains a challenging issue. The present study was designed to evaluate the cytotoxicity of 2-acetyl-7-methoxynaphtho[2,3-b]furan-4,9-quinone (AMNQ) isolated from the bark of Milletia versicolor towards a panel of drug-sensitive and multidrug-resistant (MDR) cancer cell lines. Methods The resazurin reduction assay was used to evaluate the cytotoxicity of AMNQ against 9 drug-sensitive and multidrug-resistant (MDR) cancer cell lines. Cell cycle, mitochondrial membrane potential (MMP) and levels of reactive oxygen species were all analyze…

0301 basic medicinePharmaceutical ScienceApoptosisPharmacologyFlow cytometry03 medical and health sciences0302 clinical medicineCell Line TumorDrug DiscoverymedicineHumansCytotoxic T cellCytotoxicityMembrane Potential MitochondrialPharmacologymedicine.diagnostic_testPlant ExtractsChemistryCell CycleCancerCell cyclemedicine.diseaseAntineoplastic Agents PhytogenicDrug Resistance MultipleMultiple drug resistance030104 developmental biologyComplementary and alternative medicineDoxorubicinDrug Resistance NeoplasmApoptosisCaspases030220 oncology & carcinogenesisCancer cellCancer researchMolecular MedicineReactive Oxygen SpeciesNaphthoquinonesPhytomedicine
researchProduct

Treatment of Multidrug-Resistant Leukemia Cells by Novel Artemisinin-, Egonol-, and Thymoquinone-Derived Hybrid Compounds

2018

Two major obstacles for successful cancer treatment are the toxicity of cytostatics and the development of drug resistance in cancer cells during chemotherapy. Acquired or intrinsic drug resistance is responsible for almost 90% of treatment failure. For this reason, there is an urgent need for new anticancer drugs with improved efficacy against cancer cells, and with less toxicity on normal cells. There are impressive examples demonstrating the success of natural plant compounds to fight cancer, such as Vinca alkaloids, taxanes, and anthracyclines. Artesunic acid (ARTA), a drug for malaria treatment, also exerts cytotoxic activity towards cancer cells. Multidrug resistance often results fro…

0301 basic medicinePharmaceutical ScienceDrug resistancePharmacologychemotherapyAnalytical Chemistry0302 clinical medicineartemisinin egonol thymoquinone hybridsDrug DiscoveryBenzoquinonesCytotoxic T cellCytotoxicitymedia_commonLeukemiaChemistryNaturwissenschaftliche FakultätArtemisininsDrug Resistance MultipleGene Expression Regulation NeoplasticMolecular Docking SimulationChemistry (miscellaneous)030220 oncology & carcinogenesisddc:540multi-drug resistanceMolecular Medicinemedicine.drugDrugCell Survivalmedia_common.quotation_subjectAntineoplastic AgentsArticlelcsh:QD241-44103 medical and health scienceslcsh:Organic chemistryCell Line TumormedicineHumansDoxorubicinPhysical and Theoretical Chemistrychemotherapy; multi-drug resistance; artemisinin egonol thymoquinone hybridsCell ProliferationOrganic ChemistryCancerSuccinatesmedicine.diseaseMultiple drug resistance030104 developmental biologyDoxorubicinDrug Resistance NeoplasmCancer cellATP-Binding Cassette TransportersMolecules
researchProduct

Small endogenous molecules as moiety to improve targeting of CNS drugs.

2016

A major challenge in the development of novel neuro-therapeutic agents is to effectively overcome the blood-brain barrier (BBB), which acts as a 'working dynamic barrier'. The core problem in the treatment of neurodegenerative diseases is failed delivery of potential medicines due to their inadequate permeation rate. Areas covered: The present review gives a summary of endogenous moieties used in synthesizing prodrugs, derivatives and bioisosteric drugs appositely designed to structurally resemble physiological molecular entities able to be passively absorbed or carried by specific carrier proteins expressed at BBB level. In particular, this overview focuses on aminoacidic, glycosyl, purine…

0301 basic medicinePharmaceutical ScienceEndogenyComputational biologyPharmacologyBlood–brain barrierDiffusion03 medical and health sciences0302 clinical medicinemedicinesmall endogenous moleculesMoietyCNS prodrugAnimalsHumansProdrugsmultifunctional drugbiologyMembrane transport proteinChemistryCNS carrierMembrane Transport ProteinsTranslation (biology)TransporterBiological TransportProdrug030104 developmental biologymedicine.anatomical_structurebioisosteric drugCarrier proteinSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoBlood-Brain Barrierbiology.proteinCarrier ProteinsBBB030217 neurology & neurosurgeryCentral Nervous System AgentsExpert opinion on drug delivery
researchProduct

Estrogen Receptor Signaling and the PI3K/Akt Pathway Are Involved in Betulinic Acid-Induced eNOS Activation

2016

Betulinic acid (BA) is a naturally occurring pentacyclic triterpenoid with anti-inflammatory, antiviral and anti-cancer properties. Beneficial cardiovascular effects such as increased nitric oxide (NO) production through enhancement of endothelial NO synthase (eNOS) activity and upregulation of eNOS expression have been demonstrated for this compound. In the present study, immortalized human EA.hy 926 endothelial cells were incubated for up to 1 h with 1–100 µM BA and with the phosphatidylinositol-3-kinase (PI3K) inhibitors LY294002 and wortmannin, or the estrogen receptor (ER) antagonist ICI 182,780. Phosphorylation status of eNOS and total eNOS protein were analyzed by Western blotting us…

0301 basic medicinePharmaceutical ScienceEstrogen receptorPI3KAnalytical ChemistryWortmanninchemistry.chemical_compound0302 clinical medicineEnosDrug DiscoveryLY294002PhosphorylationFulvestrantLungbiologyEstradiolendothelial cellsReceptors EstrogenChemistry (miscellaneous)030220 oncology & carcinogenesisMolecular MedicinePhosphorylationSignal transductionPentacyclic TriterpenesWortmanninSignal Transductionestrogen receptormedicine.medical_specialtyNitric Oxide Synthase Type IIIMorpholinesArticleCell Linelcsh:QD241-44103 medical and health sciencesbetulinic acidlcsh:Organic chemistryInternal medicinemedicineAnimalsHumansPhysical and Theoretical ChemistryProtein kinase BPI3K/AKT/mTOR pathwayendothelial nitric oxide synthaseAktOrganic ChemistryFibroblastsbiology.organism_classificationMolecular biologyTriterpenesbetulinic acid; endothelial nitric oxide synthase; endothelial cells; estrogen receptor; PI3K; AktRatsAndrostadienes030104 developmental biologyEndocrinologychemistryGene Expression RegulationChromonesPhosphatidylinositol 3-KinaseProto-Oncogene Proteins c-aktMolecules
researchProduct

Reprint of "EXOSOME LEVELS IN HUMAN BODY FLUIDS: A TUMOR MARKER BY THEMSELVES?"

2017

Despite considerable research efforts, the finding of reliable tumor biomarkers remains challenging and unresolved. In recent years a novel diagnostic biomedical tool with high potential has been identified in extracellular nanovesicles or exosomes. They are released by the majority of the cells and contain detailed molecular information on the cell of origin including tumor hallmarks. Exosomes can be isolated from easy accessible body fluids, and most importantly, they can at once provide with several biomarkers, with different levels of specificity. Recent clinical evidence shows that the levels of exosomes released into body fluids may by themselves represent a predictive/diagnostic of t…

0301 basic medicinePharmaceutical ScienceExosomesExosome03 medical and health sciencesProstate cancerTumor Biomarkers0302 clinical medicineMedicineHigh potentialTumor markerProstate cancerbusiness.industryFollow-upCancerExtracellular vesiclesEarly diagnosismedicine.diseaseMicrovesiclesBody fluids030104 developmental biologyClinical evidence030220 oncology & carcinogenesisImmunologyCancer researchbusinessBiomarkersEuropean journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
researchProduct